Reduction of cytotoxicity of benzalkonium chloride and octenidine by Brilliant Blue G

Authors

  • Melinda Bartok Molecular Life Science Research Center, Jacobs University Bremen, Campus Ring 1, 28759, Bremen, Germany
  • Rashmi Tandon Molecular Life Science Research Center, Jacobs University Bremen, Campus Ring 1, 28759, Bremen, Germany
  • Gabriela Alfaro-Espinoza Molecular Life Science Research Center, Jacobs University Bremen, Campus Ring 1, 28759, Bremen, Germany
  • Matthias S. Ullrich Molecular Life Science Research Center, Jacobs University Bremen, Campus Ring 1, 28759, Bremen, Germany
  • Detlef Gabel Molecular Life Science Research Center, Jacobs University Bremen, Campus Ring 1, 28759, Bremen, Germany

DOI:

https://doi.org/10.17179/excli2014-556

Keywords:

Brilliant Blue G, Brilliant Blue R, Benzalkonium chloride, Octenidine dihydrochloride, P2x7 receptor antagonist

Abstract

The irritative effects of preservatives found in ophthalmologic solution, or of antiseptics used for skin disinfection is a consistent problem for the patients. The reduction of the toxic effects of these compounds is desired. Brilliant Blue G (BBG) has shown to meet the expected effect in presence of benzalkonium chloride (BAK), a well known preservative in ophthalmic solutions, and octenidine dihydrochloride (Oct), used as antiseptic in skin and wound disinfection. BBG shows a significant protective effect on human corneal epithelial (HCE) cells against BAK and Oct toxicity, increasing the cell survival up to 51 % at the highest BAK or Oct concentration tested, which is 0.01 %, both at 30 min incubation. Although BBG is described as a P2x7 receptor antagonist, other selective P2x7 receptor antagonists, OxATP (adenosine 5’-triphosphate-2’,3’-dialdehyde) and DPPH (N’-(3,5-dichloropyridin-4-yl)-3-phenylpropanehydrazide), did not reduce the cytotoxicity of neither BAK nor Oct. Therefore we assume that the protective effect of BBG is not due to its action on the P2x7 receptor. Brilliant Blue R (BBR), a dye similar to BBG, was also tested for protective effect on BAK and Oct toxicity. In presence of BAK no significant protective effect was observed. Instead, with Oct a comparable protective effect was seen with that of BBG. To assure that the bacteriostatic effect is not affected by the combinations of BAK/BBG, Oct/BBG and Oct/BBR, bacterial growth inhibition was analyzed on different Gram-negative and Gram-positive bacteria. All combinations of BAK or Oct with BBG hinder growth of Gram-positive bacteria. The combinations of 0.001 % Oct and BBR above 0.025 % do not hinder the growth of B. subtilis. For Gram-negative bacteria, BBG and BBR reduce, but do not abolish, the antimicrobial effect of BAK nor of Oct. In conclusion, the addition of BBG at bacterial inhibitory concentrations is suggested in the ready-to-use ophthalmic preparations and antiseptic solutions.

Downloads

Published

2015-01-21

How to Cite

Bartok, M., Tandon, R., Alfaro-Espinoza, G., Ullrich, M. S., & Gabel, D. (2015). Reduction of cytotoxicity of benzalkonium chloride and octenidine by Brilliant Blue G. EXCLI Journal, 14, 123–132. https://doi.org/10.17179/excli2014-556

Issue

Vol. 14 (2015)

Section

Original articles

License

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).